JAMP TELMISARTAN-HCT: Affected lots may contain higher dosage than the labelled dose

Possible presence of tablets containing only the hydrochlorothiazide layer in the affected lot which may also result in a higher dosage than the labelled dose of 12.5 mg.

Product quality

Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns. Contact the recalling firm if you have any questions about the recall. Report any health product related side effects to Health Canada. Report any other health product safety complaints to Health Canada.

JAMP TELMISARTAN-HCT

RA-74945